Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG

RSS

tenecteplase

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 05/12/2005

Authorisation details

Product details
Name
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
Agency product number
EMEA/H/C/000307
Active substance
tenecteplase
International non-proprietary name (INN) or common name
tenecteplase
Therapeutic area (MeSH)
Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01AD
Publication details
Marketing-authorisation holder
Boehringer Ingelheim International GmbH
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
23/02/2001
Contact address
Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany

Product information

09/08/2005 Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG - EMEA/H/C/000307 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.

How useful was this page?

Add your rating
Average
1 rating